{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:11:23Z","timestamp":1792746683844,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euros.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:55:22Z","timestamp":1787586922000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oncologic Outcomes in a Contemporary \u201cPROTEUS-like\u201d Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1486-183X","authenticated-orcid":false,"given":"Can","family":"Aydogdu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benso","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Seizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Kolligs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iason","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Steinestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Westhofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.08.001_b0005","unstructured":"J, F., et al. Global Cancer Observatory: Cancer Today (version 1.1). 2024 25.06.2025]; Available from: https:\/\/gco.iarc.who.int\/today."},{"key":"10.1016\/j.euros.2026.08.001_b0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urolonc.2019.12.014","article-title":"Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy","volume":"38","author":"Knipper","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.08.001_b0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part i: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0045","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.001_b0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.24118","article-title":"Targeting backdoor androgen synthesis through AKR1C3 inhibition: a presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer","volume":"81","author":"Graham","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2026.08.001_b0030","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.35170","volume":"130","author":"McKay","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.euros.2026.08.001_b0035","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-23-0731","article-title":"Neoadjuvant Cabazitaxel plus Abiraterone\/Leuprolide Acetate in patients with high-risk prostate cancer: ACDC-RP Phase II Trial","volume":"29","author":"Fleshner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2026.08.001_b0040","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.08.001_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.08.001_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21575","volume":"40","author":"Kibel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.001_b0065","volume":"37","author":"Taplin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.001_b0070","doi-asserted-by":"crossref","unstructured":"Taplin ME, Gleave M, Shore ND, et al. Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. In press. https:\/\/doi.org\/10.1056\/NEJMoa2603878.","DOI":"10.1056\/NEJMoa2603878"},{"key":"10.1016\/j.euros.2026.08.001_b0075","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2012.08.054","article-title":"Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis","volume":"63","author":"Briganti","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0085","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.08.001_b0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2015.06.020","article-title":"Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients","volume":"68","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euros.2026.08.001_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: definition and outcomes","volume":"17","author":"Sundi","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euros.2026.08.001_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1464-410X.2009.08698.x","article-title":"Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial","volume":"105","author":"Yee","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.08.001_b0110","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.001_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102346","article-title":"Efficacy of neoadjuvant hormonal therapy for high-risk prostate cancer undergoing robot-assisted radical prostatectomy: a retrospective multicenter study using propensity score-matched analysis in Japan","volume":"23","author":"Nezasa","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2026.08.001_b0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/JU.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.08.001_b0125","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JU.0000000000002803","article-title":"Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis","volume":"208","author":"Ravi","year":"2022","journal-title":"J Urol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:26:25Z","timestamp":1790825185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S2666168326006683"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.001","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncologic Outcomes in a Contemporary \u201cPROTEUS-like\u201d Cohort of High-risk Prostate Cancer Treated with Radical Prostatectomy Without Neoadjuvant Hormonal Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}